Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Zealand Pharma A/S    ZEAL   DK0060257814

ZEALAND PHARMA A/S

(ZEAL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
07/31/2020 08/03/2020 08/04/2020 08/05/2020 08/06/2020 Date
218.4(c) 223.2(c) 219.4(c) 219(c) 220.2 Last
64 202 88 213 78 250 52 894 3 590 Volume
+0.83% +2.20% -1.70% -0.18% +0.55% Change
More quotes
Financials
Sales 2020 346 M 54,8 M 54,8 M
Net income 2020 -613 M -97,2 M -97,2 M
Net cash position 2020 747 M 118 M 118 M
P/E ratio 2020 -13,3x
Yield 2020 -
Sales 2021 296 M 46,9 M 46,9 M
Net income 2021 -714 M -113 M -113 M
Net cash position 2021 628 M 99,7 M 99,7 M
P/E ratio 2021 -11,5x
Yield 2021 -
Capitalization 8 704 M 1 375 M 1 381 M
EV / Sales 2020 23,0x
EV / Sales 2021 27,3x
Nbr of Employees 191
Free-Float 99,7%
More Financials
Company
Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and... 
More about the company
Surperformance© ratings of Zealand Pharma A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on ZEALAND PHARMA A/S
08/03Zealand Pharma Continues to Build Investor Relations and Communications Funct..
GL
07/06Zealand Pharma Expands U.S. Operations, Opens New Boston Office
GL
06/24ZEALAND PHARMA A/S : announces first patient dosed in Phase 2 trial with long-ac..
AQ
06/23ZEALAND PHARMA MAJOR SHAREHOLDER ANN : Sunstone Life Science Ventures
AQ
06/22ZEALAND PHARMA A/S : completes registration of capital increase
AQ
06/17ZEALAND PHARMA A/S : announces completion of directed issue and private placemen..
AQ
06/17ZEALAND PHARMA A/S : announces directed issues and private placements of up to a..
AQ
06/15ZEALAND PHARMA A/S : increases its share capital as a consequence of exercise of..
AQ
06/15Zealand Pharma strengthens executive team with new U.S. leadership
GL
06/14Zealand Pharma presents clinical and non-clinical evidence for dasiglucagon r..
GL
06/13ZEALAND PHARMA A/S : presents elaborated results on the use of regular human ins..
AQ
06/12ZEALAND PHARMA A/S : increases its share capital as a consequence of exercise of..
AQ
06/10Zealand Pharma to leverage Intomics bioinformatics platform within peptide dr..
GL
06/01Zealand Pharma to attend Jefferies and Goldman Sachs Virtual Healthcare Confe..
GL
05/26ZEALAND PHARMA A/S : increases its share capital as a consequence of exercise of..
AQ
More news
News in other languages on ZEALAND PHARMA A/S
08/03Zealand Pharma Continues to Build Investor Relations and Communications Funct..
07/06ZEALAND PHARMA : va ouvrir des bureaux à Boston
07/06Zealand Pharma Expands U.S. Operations, Opens New Boston Office
06/24ZEALAND PHARMA A/S : announces first patient dosed in Phase 2 trial with long-ac..
06/23ZEALAND PHARMA MAJOR SHAREHOLDER ANN : Sunstone Life Science Ventures
More news
Chart ZEALAND PHARMA A/S
Duration : Period :
Zealand Pharma A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZEALAND PHARMA A/S
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 292,57 DKK
Last Close Price 219,40 DKK
Spread / Highest target 80,0%
Spread / Average Target 33,4%
Spread / Lowest Target 2,55%
EPS Revisions
Managers
NameTitle
Emmanuel Dulac President & Chief Executive Officer
Alf Gunnar Martin Nicklasson Chairman
Ivan M. Møller Senior VP-Technical Development & Operations
Matthew D. Dallas Chief Financial Officer & Senior Vice President
Adam Sinding Steensberg Chief Medical & Development Officer, Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
ZEALAND PHARMA A/S-6.80%1 375
GILEAD SCIENCES, INC.9.08%87 217
VERTEX PHARMACEUTICALS25.92%70 523
REGENERON PHARMACEUTICALS72.69%64 189
WUXI APPTEC CO., LTD.73.65%37 214
GENMAB A/S52.01%23 205